来自官方财务报表的收入、利润与现金流历史。
Stryker Corporation 作为一家医疗技术公司在美国和国际上运营。它通过两个部门运营：医疗外科和神经技术部门以及骨科部门。 MedSurg 和神经技术部门提供手术设备、患者和护理人员安全技术、导航系统、内窥镜和通信系统、患者处理、紧急医疗设备和重症监护一次性产品、临床通信和人工智能辅助虚拟护理平台技术，以及用于治疗急性缺血性和出血性中风和静脉血栓栓塞的微创产品；传统的脑部和开放式颅骨外科手术产品；骨科生物和生物外科产品，包括合成骨移植和椎体增强产品。骨科部门提供用于全关节置换的植入物，例如髋关节、膝关节、肩关节、踝关节以及创伤和四肢手术； Mako Shoulder 扩展了智能机器人应用套件。该公司通过公司旗下的子公司和分支机构以及遍布约 61 个国家的第三方经销商和分销商向医生、医院和其他医疗机构销售其产品。 Stryker Corporation 成立于 1941 年，总部位于密歇根州波蒂奇。
机器翻译
| 利润表 | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 总收入 | $25.8B | $25.1B | $22.6B | $20.5B | $18.4B | $17.1B | $14.4B | $14.9B | $13.6B | $12.4B | $11.3B | $9.9B | $9.7B | $9.0B | $8.7B | $8.3B | $7.3B | $6.7B | $6.7B | $6.0B | $5.4B |
| 毛利 | $16.8B | $16.1B | $14.0B | $12.5B | $11.0B | $10.7B | $8.8B | $9.4B | $8.6B | $7.9B | $7.2B | $6.4B | $6.2B | $5.9B | $5.8B | $5.5B | $5.0B | $4.5B | $4.5B | $4.1B | $3.5B |
| 毛利率% | 65.2% | 64.0% | 61.9% | 61.0% | 59.8% | 62.6% | 61.0% | 63.0% | 63.2% | 63.5% | 64.0% | 64.2% | 64.3% | 65.9% | 66.7% | 66.4% | 68.0% | 67.0% | 67.7% | 68.2% | 65.0% |
| 营业利润（EBIT） | $5.7B | $4.9B | $5.1B | $4.3B | $3.7B | $3.8B | $3.0B | $3.4B | $3.1B | $2.8B | $2.6B | $2.3B | $2.2B | $2.1B | $1.9B | $2.0B | $1.9B | $1.7B | $1.6B | $1.3B | $1.1B |
| 营业利润率% | 22.0% | 19.5% | 22.4% | 20.9% | 20.2% | 22.0% | 21.1% | 22.8% | 22.8% | 22.2% | 22.8% | 22.6% | 23.0% | 23.3% | 22.1% | 23.7% | 25.3% | 25.6% | 23.1% | 22.1% | 20.8% |
| 净利 | $3.7B | $3.2B | $3.0B | $3.2B | $2.4B | $2.0B | $1.6B | $2.1B | $3.6B | $1.0B | $1.6B | $1.4B | $515M | $1.0B | $1.3B | $1.3B | $1.3B | $1.1B | $1.1B | $1.0B | $778M |
| 净利润率 % | 14.4% | 12.9% | 13.2% | 15.4% | 12.8% | 11.7% | 11.1% | 14.0% | 26.1% | 8.2% | 14.5% | 14.5% | 5.3% | 11.2% | 15.0% | 16.2% | 17.4% | 16.5% | 17.1% | 17.0% | 14.4% |
| EBITDA | $6.3B | $6.3B | $4.9B | $5.1B | $4.0B | $3.6B | $3.1B | $3.6B | $3.3B | $3.0B | $2.7B | $2.2B | $1.7B | $1.6B | $2.0B | $2.3B | $2.2B | $2.0B | $2.0B | $1.8B | $1.4B |
| 每股收益（EPS） | $9.65 | $8.49 | $7.76 | $8.25 | $6.17 | $5.22 | $4.20 | $5.48 | $9.34 | $2.68 | $4.35 | $3.78 | $1.35 | $2.63 | $3.39 | $3.45 | $3.19 | $2.77 | $2.78 | $2.44 | $1.89 |
| 已发行股数 (M) | 386M | 382M | 386M | 384M | 382M | 382M | 380M | 380M | 380M | 380M | 378M | 381M | 383M | 382M | 383M | 390M | 400M | 399M | 414M | 417M | 411M |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 SYK 交互式查看器。 /companies/us/SYK
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms